SCOTUS Rules Against Amgen in PCSK9 Patent Dispute with Sanofi, Regeneron

The U.S. Supreme Court unanimously ruled Amgen’s cholesterol drug Repatha patents invalid, ending a protracted legal battle with competitors Sanofi and Regeneron.

Scroll to Top